Ranbaxy Shares


'Ranbaxy Shares' - 31 News Result(s)

  • Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case

    Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case

    Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

  • "Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points

    "Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points

    The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...

  • BSE to Discontinue Trading in Ranbaxy From April 6

    BSE to Discontinue Trading in Ranbaxy From April 6

    BSE has decided to delist Ranbaxy stock from S&P BSE 100, S&P BSE 200, S&P BSE 500, S&P BSE Healthcare and S&P BSE Carbonex indices from April 6.

  • Ranbaxy Shares to Stop Trading on Bourses From April 6

    Ranbaxy Shares to Stop Trading on Bourses From April 6

    Ranbaxy Laboratories shares will stop trading on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) with effect from April 6 as the company is getting merged with Sun Pharmaceutical Industries in a $4-billion deal.

  • Ranbaxy Shares Fall 5% on US FDA Blow

    Ranbaxy Shares Fall 5% on US FDA Blow

    Analysts had expected generic Nexium to contribute about $150 million to Ranbaxy's sales in the first six months of the exclusive sales period, while Valcyte was expected to contribute between $40 million and $50 million.

  • Sun Pharma, Ranbaxy Shares Rise as Court Lifts Stay on Merger

    Sun Pharma, Ranbaxy Shares Rise as Court Lifts Stay on Merger

    The Andhra Pradesh High Court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading. The petition was filed in late April by two individuals who requested that the court ask the market regulator SEBI and the two main stock exchanges to halt the deal and order a probe.

  • Sun Pharma Denies Unit's Role in Ranbaxy Share Surge

    Sun Pharma Denies Unit's Role in Ranbaxy Share Surge

    Sun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.

  • Sun Pharma, Ranbaxy shares drop as merger put on hold

    Sun Pharma, Ranbaxy shares drop as merger put on hold

    Ranbaxy shares fell as much as 3.7 per cent in early trade on Wednesday, while shares in Sun Pharma fell as much as 2.7 per cent on the back of the decision from Andhra Pradesh High Court to maintain interim status quo on the Sun Pharma-Ranbaxy merger process.

  • Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE

    Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE

    The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street.

  • Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover

    Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover

    Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.

  • Ranbaxy's journey as a company to end after merger with Sun Pharma

    Ranbaxy's journey as a company to end after merger with Sun Pharma

    Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.

  • Sebi to ask stock exchanges for trading data in Ranbaxy shares

    Sebi to ask stock exchanges for trading data in Ranbaxy shares

    Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.

  • Probe Ranbaxy trades ahead of Sun Pharma deal: brokers

    Probe Ranbaxy trades ahead of Sun Pharma deal: brokers

    Ranbaxy shares surged 24 per cent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy Ranbaxy for $3.2 billion.

  • Sun Pharma-Ranbaxy deal: What brokerages say

    Sun Pharma-Ranbaxy deal: What brokerages say

    In a big ticket acquisition, Sun Pharma yesterday announced that it will acquire Ranbaxy in a $4 billion all-stock deal. The combined entity of Sun-Pharma and Ranbaxy will become the largest drug company in India and one of the largest speciality generics company in the world.

  • Sun Pharma shares soar 4% on Ranbaxy deal

    Sun Pharma shares soar 4% on Ranbaxy deal

    Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...

'Ranbaxy Shares' - 3 Video Result(s)

'Ranbaxy Shares' - 31 News Result(s)

  • Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case

    Ranbaxy Ex-Promoters Malvinder, Shivinder Singh Arrested In Fraud Case

    Pharmaceutical giant Ranbaxy's ex-promoters Shivinder Singh and his older brother Malvinder Singh were arrested on Thursday in a Rs 740-crore fraud case.

  • "Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points

    "Will Send You To Jail," Ranbaxy Singh Brothers Told By Court: 10 Points

    The former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh, were told by the Supreme Court today that they could go to jail for disobeying orders to pay dues to Japanese firm Daiichi Sankyo. "We will go into the issue - why you violated our orders. We will send you to jail. We have given you ...

  • BSE to Discontinue Trading in Ranbaxy From April 6

    BSE to Discontinue Trading in Ranbaxy From April 6

    BSE has decided to delist Ranbaxy stock from S&P BSE 100, S&P BSE 200, S&P BSE 500, S&P BSE Healthcare and S&P BSE Carbonex indices from April 6.

  • Ranbaxy Shares to Stop Trading on Bourses From April 6

    Ranbaxy Shares to Stop Trading on Bourses From April 6

    Ranbaxy Laboratories shares will stop trading on Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) with effect from April 6 as the company is getting merged with Sun Pharmaceutical Industries in a $4-billion deal.

  • Ranbaxy Shares Fall 5% on US FDA Blow

    Ranbaxy Shares Fall 5% on US FDA Blow

    Analysts had expected generic Nexium to contribute about $150 million to Ranbaxy's sales in the first six months of the exclusive sales period, while Valcyte was expected to contribute between $40 million and $50 million.

  • Sun Pharma, Ranbaxy Shares Rise as Court Lifts Stay on Merger

    Sun Pharma, Ranbaxy Shares Rise as Court Lifts Stay on Merger

    The Andhra Pradesh High Court last month ordered an "interim status quo" on the deal, pending a decision on a petition for a probe into alleged insider trading. The petition was filed in late April by two individuals who requested that the court ask the market regulator SEBI and the two main stock exchanges to halt the deal and order a probe.

  • Sun Pharma Denies Unit's Role in Ranbaxy Share Surge

    Sun Pharma Denies Unit's Role in Ranbaxy Share Surge

    Sun Pharma said it had "no access to non-public information of Ranbaxy" when its unit Silverstreet bought shares in Ranbaxy.

  • Sun Pharma, Ranbaxy shares drop as merger put on hold

    Sun Pharma, Ranbaxy shares drop as merger put on hold

    Ranbaxy shares fell as much as 3.7 per cent in early trade on Wednesday, while shares in Sun Pharma fell as much as 2.7 per cent on the back of the decision from Andhra Pradesh High Court to maintain interim status quo on the Sun Pharma-Ranbaxy merger process.

  • Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE

    Maintain status-quo on Sun Pharma-Ranbaxy merger: Court to BSE, NSE

    The petitioners alleged that there was heavy trading of Ranbaxy stock before the merger with Sun Pharma was announced on April 6, and requested the court to direct the SEBI to investigate the insider trading of Ranbaxy shares and take appropriate action against Sun Pharma and Silver Street.

  • Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover

    Nomura raises Ranbaxy to 'buy' on Sun Pharma takeover

    Although Nomura says Ranbaxy shares look expensive on valuation, it notes the stock should now move in tandem with Sun Pharma, hence the steep increase in its target price.

  • Ranbaxy's journey as a company to end after merger with Sun Pharma

    Ranbaxy's journey as a company to end after merger with Sun Pharma

    Sun Pharma said on April 7 it would fully acquire Ranbaxy, which was incorporated in 1961 and went public in 1973. It will offer 0.8 share of Sun Pharma for each Ranbaxy share, representing an implied value of Rs 457 per Ranbaxy share.

  • Sebi to ask stock exchanges for trading data in Ranbaxy shares

    Sebi to ask stock exchanges for trading data in Ranbaxy shares

    Ranbaxy shares had surged 24 percent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy it for $3.2 billion.

  • Probe Ranbaxy trades ahead of Sun Pharma deal: brokers

    Probe Ranbaxy trades ahead of Sun Pharma deal: brokers

    Ranbaxy shares surged 24 per cent in the three trading sessions leading up to the announcement on Monday that Sun Pharmaceutical had agreed to buy Ranbaxy for $3.2 billion.

  • Sun Pharma-Ranbaxy deal: What brokerages say

    Sun Pharma-Ranbaxy deal: What brokerages say

    In a big ticket acquisition, Sun Pharma yesterday announced that it will acquire Ranbaxy in a $4 billion all-stock deal. The combined entity of Sun-Pharma and Ranbaxy will become the largest drug company in India and one of the largest speciality generics company in the world.

  • Sun Pharma shares soar 4% on Ranbaxy deal

    Sun Pharma shares soar 4% on Ranbaxy deal

    Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...

Your search did not match any documents
A few suggestions
  • Make sure all words are spelled correctly
  • Try different keywords
  • Try more general keywords
Check the NDTV Archives:https://archives.ndtv.com

................................ Advertisement ................................

................................ Advertisement ................................

Listen to the latest songs, only on JioSaavn.com